A 2X2 FACTORIAL, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE NEUROMODULATORS AND COUGH CONTROL THERAPY IN PATIENTS WITH REFRACTORY OR UNEXPLAINED CHRONIC COUGH: THE FORTITUDE TRIAL
- Registry ID
- FORTITUDE-01
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Study type
- INTERVENTIONAL
- Sponsor
- MCMASTER UNIVERSITY
- Last update
- 2025-11-27
Conditions
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NALBUPHINE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF PARTICIPANTS WITH REFRACTORY CHRONIC COUGH
- A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELARM EFFICACY AND SAFETY STUDY WITH OPEN-LABEL EXTENSION OF BLU-5937 IN ADULT
PARTICIPANTS WITH REFRACTORY CHRONIC COUGH INCLUDING UNEXPLAINED CHRONIC
COUGH (CALM-2)
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE
EFFICACY, SAFETY, AND TOLERABILITY OF TAPLUCAINIUM INHALATION POWDER (NOC-110)
IN ADULTS WITH REFRACTORY OR UNEXPLAINED CHRONIC COUGH
View on source registry